EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32

Pamela J Goodwin iD, Bingshu E Chen iD, Karen A Gelmon, Timothy J Whelan, Marguerite Ennis iD, Jennifer Ligibel, Paul M Stos, Lois E Shepherd, Wendy R Parulekar, Vuk Stambolic

JNCI Cancer Spectrum · 03.09.2026 · 10 (5)

DOI: 10.1093/jncics/pkag068 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 25.06.2026. Verfasst von Pamela J Goodwin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Lunenfeld-Tanenbaum Research Institute, Sinai Health System, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Mucin-1, Triple Negative Breast Neoplasms, Breast Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Institute (US), Breast Cancer Research Foundation, Canadian Breast Cancer Foundation-Ontario Region, Ontario Institute for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating levels of cancer antigen (CA) 15-3 have been associated with distant breast cancer recurrence; data on breast cancer subtypes are sparse. We examined associations of CA 15-3 with outcomes across immunohistochemically defined breast cancer subtypes in MA.32.

Methods

A total of 3649 participants with T1-3, N0-1, M0 breast cancer were randomly assigned; 2740 (75.1%) provided blood at entry (mean = 278 days postdiagnosis) and 6 months later. Prognostic associations of baseline and 6-month change in CA 15-3 with distant recurrence-free survival (RFS) were examined in luminal (estrogen receptor–positive and/or progesterone receptor–positive, HER2-negative), triple-negative (estrogen receptor, progesterone receptor, HER2 negative) and HER2-positive (any estrogen receptor, progesterone receptor) breast cancer using Cox proportional hazards models.

Results

Mean age was 52 years. Breast cancer was luminal in 1589 (58.7%), triple negative in 655 (24.2%), and HER2 positive in 464 (17.1%) participants. Median follow-up was 96 months. CA 15-3 at study entry was not associated with outcome in any subtype. Rising CA 15-3 at 6 months was associated with poor distant RFS in luminal and triple-negative breast cancer (hazard ratio [HR] per 25% increase = 1.41, P < .0001, and HR = 1.35, P < .0001, respectively). New elevations in CA 15-3 at 6 months were adversely associated with distant RFS in those with luminal or triple-negative breast cancer (HR = 4.14, 95% CI = 2.69 to 6.38; P < .001; and HR = 3.57, 95% CI = 1.59 to 7.99; P = .002, respectively). In HER2-positive breast cancer, CA15-3 was not associated with distant RFS.

Conclusion

Rising CA 15-3 was associated with reduced distant RFS in luminal and triple-negative breast cancer but not in HER2-positive breast cancer. Clinical Trial Registration ClinicalTrials.gov NCT01101438

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucin-1Triple Negative Breast NeoplasmsBreast NeoplasmsNeoplasm Recurrence, LocalBiomarkers, TumorHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenProportional Hazards ModelsAdultDisease-Free SurvivalAgedImmunohistochemistryCanadaPrognosis

Substanzen

Mucin-1Erb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medicine and Lunenfeld-Tanenbaum Research Institute, Sinai Health System, University of Toronto, Toronto, ON, Canada.
  • Canadian Cancer Trials Group, Department of Public Health Sciences, Queens University, Kingston, ON, Canada.
  • Department of Medical Oncology, BC Cancer Agency and Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada.
  • Applied Statistician, Markham, ON, Canada.
  • Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard University, Boston, MA, United States.

ORCID-Profile: Pamela J Goodwin, Bingshu E Chen, Marguerite Ennis

Förderung

  • National Cancer Institute (US)
  • Breast Cancer Research Foundation
  • Canadian Breast Cancer Foundation-Ontario Region, Ontario Institute for Cancer Research
  • Canadian Cancer Society Research Institute
  • NCI NIH HHS
  • Apotex Canada
  • Hold'em for Life Charity
  • Canadian Breast Cancer Foundation—Ontario Region, Ontario Institute for Cancer Research

Zitieren

APA

Goodwin, P. J., Chen, B. E., Gelmon, K. A., Whelan, T. J., Ennis, M., Ligibel, J., Stos, P. M., Shepherd, L. E., Parulekar, W. R., & Stambolic, V. (2026). Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32. JNCI Cancer Spectrum, 10(5). https://doi.org/10.1093/jncics/pkag068

Vancouver

Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Ligibel J, et al. Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32. JNCI Cancer Spectrum. 2026;10(5). doi:10.1093/jncics/pkag068

BibTeX
@article{Goodwin2026,
  author = {Goodwin, Pamela J and Chen, Bingshu E and Gelmon, Karen A and Whelan, Timothy J and Ennis, Marguerite and Ligibel, Jennifer and Stos, Paul M and Shepherd, Lois E and Parulekar, Wendy R and Stambolic, Vuk},
  title = {Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  volume = {10},
  number = {5},
  doi = {10.1093/jncics/pkag068}
}
Kostenlos starten →